Chronic venous insufficiency treatment
The Cochrane review of 17 RCTs (2,069 patients) established HCSE as an effective treatment for CVI — with meta-analysis confirming significant reductions in leg pain (SMD -0.42), leg edema/swelling (WMD -9.4 mL), and leg fatigue vs. placebo. One trial demonstrated equivalence to compression stockings over 12 weeks — making HCSE the only oral botanical with compression-equivalent efficacy data.
Leg edema and swelling reduction
HCSE significantly reduces lower leg edema volume — measurable by water displacement plethysmography — through reduction of venous capillary permeability and restoration of normal transcapillary fluid dynamics. Clinically meaningful edema reduction is typically observed within 4 weeks of treatment initiation.
Varicose vein symptom relief
Beyond the underlying venous insufficiency, HCSE significantly reduces the symptoms of varicose veins — including aching, heaviness, pruritus (itching), and cramping — improving quality of life in affected patients. These symptomatic benefits correlate with the measurable reduction in capillary filtration and improved venous tone.
Post-surgical and post-traumatic edema
Aescin administered intravenously (in European clinical practice) and orally significantly reduces post-surgical and post-traumatic swelling. Both the anti-edema and venotonic properties of aescin are beneficial in the inflammatory edema that follows tissue injury or surgical intervention.
Capillary permeability reduction via enzyme inhibition
Aescin inhibits hyaluronidase and elastase — enzymes that degrade glycosaminoglycans in the capillary wall matrix. By protecting the capillary basement membrane from enzymatic degradation, aescin reduces capillary leakage of plasma proteins and fluid into the interstitium, directly reducing edema formation.
Venotonic activity and venous wall strengthening
Aescin increases venous tone by reducing prostaglandin E2-mediated venous wall relaxation — a mechanism that improves venous return from the legs to the heart. Simultaneously, aescin strengthens the collagen structure of the venous wall by activating collagen synthesis and cross-linking, improving the structural integrity of varicose veins.
Anti-inflammatory and free radical scavenging in venous tissue
Aescin inhibits NF-κB activation in venous endothelial cells, reducing inflammatory cytokine production that drives venous wall damage in CVI. Antioxidant protection of venous endothelium reduces the oxidative stress component of venous insufficiency pathology.
Cochrane systematic review of 17 RCTs (2,069 patients) examining HCSE for chronic venous insufficiency.
2,069 CVI patients across 17 RCTs.
HCSE significantly reduced leg pain (SMD -0.42), leg edema (-9.4 mL WMD), and leg fatigue vs. placebo. One trial showed HCSE equivalent to compression stockings for leg volume reduction over 12 weeks. No serious adverse events. Established HCSE as evidence-based CVI treatment.
Three-arm, randomized trial comparing HCSE (Venostasin®) vs. compression stockings vs. placebo in 240 CVI patients for 12 weeks.
240 CVI patients. 12-week three-arm trial.
Leg volume reduction equivalent between HCSE and compression stockings groups. Both significantly better than placebo. HCSE preferred by patients (vs. stockings) for convenience. Provides first clinical comparison establishing botanical equivalence to mechanical compression.